Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Benralizumab for Bronchiectasis
Recruiting1 awardPhase 3
Washington, District of Columbia
This trial is testing if a drug called benralizumab can help reduce exacerbation rates for people with non-cystic fibrosis bronchiectasis who also have eosinophilic inflammation. The trial will last for 52 weeks, and patients who complete the trial will be eligible for an extension where they will receive the drug for at least one more year.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.